Edwyn
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | $213 | $196 | $188 | $172 | $317 |
| Gross Profit | $151 | $135 | $154 | $140 | $231 |
| Operating Income | $37 | $22 | $33 | $3 | $81 |
| Net Income | $32 | $14 | $12 | -$9 | $36 |
Over the five-year period, Eagle Pharmaceuticals’ revenues and profit metrics experienced notable fluctuations. In 2018, the company posted healthy revenue of $213.3 million and strong gross and operating margins, with gross profit and operating income at $151.4 million and $36.6 million, respectively. However, by 2019, revenue declined by about 8% to $195.9 million, accompanied by a roughly 11% drop in gross profit and a sharper decline in operating income (about 40%), which resulted in net income falling from $31.9 million to $14.3 million—a swing exceeding 50%. In 2020, although revenue fell further to $187.8 million, gross profit rebounded to $154.2 million and operating income improved to $33.0 million, suggesting some operational efficiencies. Yet, 2021 saw a sharp deterioration, with revenue dropping to $171.5 million, operating income plunging to merely $2.8 million, and net income turning negative at -$8.6 million, indicating significant cost pressures or other challenges. The turnaround in 2022 was striking; revenue surged by approximately 84% to $316.6 million, and gross profit increased by about 65% to $231.2 million. This strong recovery was further underscored by operating income jumping to $81.0 million and net income rebounding to $35.6 million. These data points suggest that after a period of contraction and operational challenges, Eagle Pharmaceuticals managed to realign its business strategy effectively. Considering the recovery trends and strong performance in 2022, the company appears to be on a more sustainable path, provided that underlying operational issues from the prior year have been adequately addressed.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.